ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
10.52
+0.27 (2.63%)
At close: May 1, 2026, 4:00 PM EDT
10.52
0.00 (-0.01%)
After-hours: May 1, 2026, 7:59 PM EDT
ADMA Biologics Revenue
In the year 2025, ADMA Biologics had annual revenue of $510.17M with 19.63% growth. ADMA Biologics had revenue of $139.16M in the quarter ending December 31, 2025, with 18.39% growth.
Revenue (ttm)
$510.17M
Revenue Growth
+19.63%
P/S Ratio
4.79
Revenue / Employee
$788,521
Employees
647
Market Cap
2.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 510.17M | 83.72M | 19.63% |
| Dec 31, 2024 | 426.45M | 168.24M | 65.15% |
| Dec 31, 2023 | 258.22M | 104.14M | 67.59% |
| Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
| Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
| Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
| Dec 31, 2019 | 29.35M | 12.36M | 72.79% |
| Dec 31, 2018 | 16.99M | -5.78M | -25.37% |
| Dec 31, 2017 | 22.76M | 12.10M | 113.49% |
| Dec 31, 2016 | 10.66M | 3.48M | 48.53% |
| Dec 31, 2015 | 7.18M | 1.26M | 21.33% |
| Dec 31, 2014 | 5.92M | 2.85M | 92.84% |
| Dec 31, 2013 | 3.07M | 1.95M | 174.35% |
| Dec 31, 2012 | 1.12M | 357.08K | 46.92% |
| Dec 31, 2011 | 761.04K | - | - |
| Jun 30, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Ultragenyx Pharmaceutical | 673.00M |
| Zai Lab | 460.16M |
| IDEAYA Biosciences | 218.71M |
| Relay Therapeutics | 15.36M |
| Immunome | 6.94M |
| Celldex Therapeutics | 1.55M |
ADMA News
- 1 day ago - Investor Notice: ADMA Biologics (NASDAQ:ADMA) may have Committed Securities Fraud after Channel Stuffing Claims Disclosed – Contact BFA Law about the Pending Investigation - GlobeNewsWire
- 3 days ago - ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 - GlobeNewsWire
- 3 days ago - $ADMA Fraud: ADMA Biologics Channel Stuffing Claims Trigger Securities Investigation – Investors Alerted to Contact BFA Law - GlobeNewsWire
- 5 days ago - ADMA Stock: ADMA Biologics Securities Fraud Investigation is Ongoing – Investors with Losses Urged to Contact BFA Law - GlobeNewsWire
- 10 days ago - $ADMA Investigation: BFA Law Notifies ADMA Biologics Investors that Lost Money after 29% Stock Drop of Ongoing Securities Fraud Investigation - GlobeNewsWire
- 11 days ago - ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating - PRNewsWire
- 12 days ago - ADMA Securities News: ADMA Biologics Hit with Securities Fraud Investigation after Channel Stuffing Claims Trigger 29% Stock Drop – Investors Urged to Contact BFA Law - GlobeNewsWire
- 15 days ago - ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - GlobeNewsWire